Level C· Early human research exploring benefitsProspective StudyEurope PMC

Human stem cells for craniomaxillofacial reconstruction

Jalali M., Kirkpatrick WN., Cameron MG., Pauklin S., Vallier L.

Prospective Study on Scar, Chronic Inflammation, published in Stem Cells Dev (2014) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Stem Cells Dev (2014)
Reported sample size
—
Source database
Europe PMC
PMID
24564584
PMCID
PMC4066224
DOI
10.1089/scd.2013.0576
Citations
5

Abstract (original English)

Human stem cell research represents an exceptional opportunity for regenerative medicine and the surgical reconstruction of the craniomaxillofacial complex. The correct architecture and function of the vastly diverse tissues of this important anatomical region are critical for life supportive processes, the delivery of senses, social interaction, and aesthetics. Craniomaxillofacial tissue loss is commonly associated with inflammatory responses of the surrounding tissue, significant scarring, disfigurement, and psychological sequelae as an inevitable consequence. The in vitro production of fully functional cells for skin, muscle, cartilage, bone, and neurovascular tissue formation from human stem cells, may one day provide novel materials for the reconstructive surgeon operating on patients with both hard and soft tissue deficit due to cancer, congenital disease, or trauma. However, the clinical translation of human stem cell technology, including the application of human pluripotent stem cells (hPSCs) in novel regenerative therapies, faces several hurdles that must be solved to permit safe and effective use in patients. The basic biology of hPSCs remains to be fully elucidated and concerns of tumorigenicity need to be addressed, prior to the development of cell transplantation treatments. Furthermore, functional comparison of in vitro generated tissue to their in vivo counterpa

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
Mesenchymal Stem CellsPluripotent Stem CellsAnimalsHumansMaxillofacial AbnormalitiesCraniocerebral TraumaMesenchymal Stem Cell TransplantationRegenerative MedicineBone RegenerationCell Differentiation

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research